サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1208614

ぶどう膜炎の世界市場-2023-2030

Global Uveitis Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 200 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
ぶどう膜炎の世界市場-2023-2030
出版日: 2023年02月01日
発行: DataM Intelligence
ページ情報: 英文 200 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

ぶどう膜炎の世界市場規模は、2022年に4億5600万米ドル、2030年には8億3700万米ドルに達すると推定され、予測期間（2023年～2030年）にCAGR4.8％で成長するとされています。

ぶどう膜炎は目の炎症であり、眼球内の組織の中間層に影響を及ぼします。20歳から50歳の年齢層で発症することがほとんどです。ぶどう膜炎は、時に視力の低下につながることもある深刻な問題です。

市場力学

世界のぶどう膜炎市場を牽引する主な要因は、緑内障や白内障などの眼科疾患の発生率増加によるぶどう膜炎の需要増加、啓発活動の高まり、新薬開発や新製品の上市につながる技術の進歩です。

製薬会社の製品パイプラインの増加や、新薬の開発につながる技術の進歩の高まりは、市場の成長を促進すると期待されています。

ぶどう膜炎市場は、技術の進歩の高まり、老人人口の増加、研究開発投資の急増、緑内障、白内障、AMDなどの眼科疾患の増加、新興国市場の医療インフラの改善とともに最新技術を用いた新規製品の改善によって牽引されています。

ぶどう膜炎治療薬は、治療目的で広く使用されています。これらのデバイスの採用が増加しているため、政府の取り組みや資金の上昇につながっています。これらの資金は、目薬、注射、錠剤、インプラントなどのぶどう膜炎治療薬の生産に役立てられます。これらの眼科疾患の患者数が増加しているため、これらの医薬品の市場は世界的に拡大しています。さらに、主要企業による技術的に高度な製品の提供も、市場の成長に重要な役割を果たすと予想されます。

これらのぶどう膜炎治療薬に関連するさまざまな新製品の上市、調査研究、啓発活動の高まりは、市場の成長に寄与しています。例えば、2022年11月1日、網膜の健康やより長く良好な視力を維持する患者に焦点を当てた製薬会社であるアリメラ・サイエンス社は、アイルランドにある欧州子会社、アリメラ・サイエンス・欧州社が、販売パートナーのメディス社を通じて、非感染性ぶどう膜炎に適応を持つ徐放性眼内インプラントであるILUVIEN（fluocinolone acetonide intravitreal implant）について償還を許可されたと発表しています。

治療費の高さと副作用のリスクの高さが市場成長の妨げになると予想されます。

ぶどう膜炎に使用される医薬品の承認に関する厳しい規則や規制は、ぶどう膜炎市場の成長を阻害する主な要因です。さまざまな要件、臨床試験を満たす必要があり、これらの医薬品の全体的なコストの上昇につながっています。これらの治療法に関連する高コストは、成長を妨げる可能性があります。

また、これらの薬剤の副作用に関連する高いリスクも市場の成長を制限しています。市場のリコールもまた、市場の成長を抑制する主要な要因となっています。インプラントの漏出や合併症が原因で、いくつかのリコールが行われています。

COVID-19の影響分析

パンデミックは、世界の財務的な期待、業務、危機対応戦略に悪影響を与えています。COVID-19の発生はヘルスケア産業に深刻な影響を及ぼしています。ぶどう膜炎市場は、COVIDにより莫大な損失を経験しました。主要メーカーは様々な研究・臨床試験を開始しました。様々な取り組み、製品の上市、コラボレーション、合併が世界中で行われており、市場の成長を後押ししています。例えば、2022年10月17日、Kiora Pharmaceuticals, Inc.は、KIO-100（旧PP-001）第1相試験の結果を発表し、眼科炎症性疾患治療である非感染性ぶどう膜炎への可能性を示しました。

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場影響要因
    • 促進要因
      • 製薬会社の製品パイプラインの増加
      • 新薬開発につながる技術の進歩
    • 抑制要因
      • 治療に伴う高いコスト
      • 副作用の高いリスク
    • ビジネスチャンス
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • プライシング分析

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、または将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的取り組み
  • まとめ

第7章 ぶどう膜炎タイプ別

  • 前部ぶどう膜炎
  • 中間ぶどう膜炎
  • 後方ぶどう膜炎
  • 汎ぶどう膜炎

第8章 薬物別

  • 副腎皮質ステロイド
    • ベタメタゾン
    • デキサメタゾン
    • コルチゾン
    • トリアムシノロン
    • メチルプレドニゾロン
  • 抗リウマチ薬
    • ミコフェノラート
    • シクロスポリン
    • アザチオプリン
    • タクロリムス
  • サイクロプレンティック・散瞳薬
    • トロピカミド
    • シクロペントラート
    • フェニレフリン
    • ホマトロピン
    • アトロピン
  • 免疫調整療法
    • アザチオプリン
    • メトトレキサート
    • ミコフェノール酸モフェチル
    • シクロスポリン
  • 生物学的療法
    • インフリキシマブ
    • アダリムマブ
    • ダクリズマブ
    • インターフェロン-アルファ
  • 抗ウイルス剤
    • アシクロビル
    • バラシクロビル
  • その他

第9章 薬剤形態別

  • 点眼薬
  • 錠剤
  • 注射剤
  • インプラント

第10章 エンドユーザー別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第12章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 製品ベンチマーク
  • 注目の主要企業リスト

第13章 企業プロファイル

  • Novartis AG
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • AbbVie
  • Johnson & Johnson Services, Inc.
  • Amgen
  • Alimera Sciences
  • Bausch & Lomb Incorporated.
  • Kiora Pharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • EyePoint Pharmaceuticals, Inc.
  • Clearside Biomedical

第14章 ぶどう膜炎の世界市場-DataM

目次
Product Code: DMMD97

Market Overview

The global uveitis market size was valued at US$ 456 million in 2022 and is estimated to reach US$ 837 million by 2030, growing at a CAGR of 4.8% during the forecast period (2023-2030).

Uveitis is an eye inflammation, which affects the middle layer of the tissue in the eyewall. The majority of the alter lie in the population ages of 20 to 50 years. Uveitis can sometimes be a serious issue that can also lead to loss of vision.

Market Dynamics

The major factors driving the global uveitis market are the rising demand for uveitis owing to increasing incidences of ophthalmic disorders such as uveitis glaucoma and uveitis cataract, surging awareness initiatives, advancements in technologies leading to the development of new drugs and novel product launches.

The increasing product pipeline of pharma companies and rising technological advancements leading to the development of new drugs are expected to drive the market's growth.

The uveitis market is driven by rising advancements in technology, an increase in the geriatric population, a surge in research and development investments, an increasing number of ophthalmic disorders such as uveitis glaucoma, uveitis cataract, AMD and improvements in novel products using the latest technology along with improvements in medical infrastructure in emerging markets.

The uveitis medications are used widely for treatment purpose. The adoption of these devices is increasing, leading to rising government initiatives and funds. These funds will help produce uveitis medication products such as eye drops, injections, pills or implants. The market for these medications is increasing worldwide due to the enhanced number of these ophthalmic disorders. Moreover, the availability of technologically advanced products by key players is also expected to play a vital role in the market's growth.

Various novel product launches, research studies, and rising awareness initiatives related to these uveitis medications contribute to the market's growth. For instance, in November 1, 2022, Alimera Sciences, Inc., a pharmaceutical company focussed on patients with retinal health and maintaining longer and better vision, announced that its Ireland-based European subsidiary, Alimera Sciences Europe Limited, has been granted reimbursement for ILUVIEN (fluocinolone acetonide intravitreal implant) which is a sustained release intravitreal implant indicated for non-infectious uveitis, via Medis Pharmaceutical Company, its distribution partner.

High cost associated with the treatment and high risk of side effects are expected to hamper the market's growth.

Strict rules and regulations for the approval of medications utilized for uveitis is the major factor hindering the growth of the uveitis market. Various requirements, clinical trials must be fulfilled, leading to an increase in the overall cost of these medications. The high cost associated with these treatments is likely to hinder the growth.

High risk related to side effects of these medications is also limiting market's growth. Market recalls are also a leading factor restraining the growth of the market. Several recalls are taking place due to leakage or complications in implants.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The uveitis market has experienced huge losses due to COVID. Key manufacturers have started various research and clinical trials. Various initiatives, product launches, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in October 17, 2022, Kiora Pharmaceuticals, Inc. announced its results from KIO-100 (formerly PP-001) Phase 1 study, showing its potential for non-infectious uveitis, an ophthalmic inflammatory disease treatment.

Segment Analysis

The anterior uveitis segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The anterior uveitis segment is the highest market holder in the global uveitis market. The global uveitis market is segmented based on disease type as anterior uveitis, intermediate uveitis, posterior uveitis and pan uveitis. The anterior uveitis segment is the largest market shareholder due to its increasing number of incidences globally, increasing technological advancements and novel product launches.

Anterior uveitis is the most common kind of uveitis which mostly affects the ciliary body and the inside of the front of eye (between the iris and the cornea). It is also also known as iritis. Anterior uveitis can be caused due to a trauma to the eye, like getting hit in the eye or having a foreign particle in the eye. It is also linked with common health problems including syphilis, rheumatoid arthritis, tuberculosis and viral (herpes simplex). Its symptoms include blurred vision, red or inflamed eye, small, irregular-shaped pupil and sensitivity to light.

The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drives the market's growth. For instance, in March 28, 2022, Bausch + Lomb, Bausch Health Companies' eye health business and Clearside Biomedical, Inc. a biopharmaceutical company transforming the therapies' delivery to the back of the eye via the suprachoroidal space (SCS) announced the commercial launch of XIPERE (triamcinolone acetonide injectable suspension) in U.S., the first therapy which got approval for suprachoroidal use by the U.S. Food and Drug Administration (FDA) for the macular edema associated with uveitis treatment.

Geographical Analysis

North America holds the largest market share in the global uveitis market.

North America dominates the global uveitis market primarily due to its large population, excellent medical infrastructure, and high-income levels. The market is expected to grow at a relatively moderate pace during the forecast period due to healthcare expenditure in the US. The market's significant size is attributed to the high medical expenditure.

Increasing expenditure on healthcare and raising awareness among people is also contributing to the market's growth in this region. Advancement of uveitis medications in several ophthalmic conditions like uveitis glaucoma or uveitis cataract, increase in pharmaceutical establishment across the region and government approvals, and the presence of key players in the region are contributing to the growth of the uveitis market.

Moreover, the growing number of product launches is responsible for the market's growth. Many key developments, technological advancements, collaborations, and agreements are taking place in this region. For instance, in August 8, 2022, Clearside Biomedical, Inc., a biopharmaceutical company transforming the therapies' delivery to the back of the eye via the suprachoroidal space (SCS), announced about entering into a sale agreement with HealthCare Royalty Partners.

Competitive Landscape

The uveitis market is highly competitive with local and global companies' presence. Novartis Inc., AbbVie, Johnson & Johnson Services, Inc., Amgen, Alimera Sciences, Bausch & Lomb Incorporated., Kiora Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., EyePoint Pharmaceuticals, Inc., Clearside Biomedical and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in September 23, 2022, Alimera Sciences, Inc., a pharmaceutical company focussed on patients with retinal health and maintaining longer and better vision, announced its agreement with the Jaeb Center for Health Research Foundation Inc. (JCHR), to support and provide ILUVIEN (fluocinolone acetonide intravitreal implant) intravitreal implant for "A randomized clinical trial evaluating fluocinolone acetonide intravitreal implants or intravitreal faricimab injections vs due to Radiation Retinopathy visual acuity loss prevention observation.

Novartis AG

Overview: Novartis is engaged in discovering, developing, manufacturing, and selling a wide range of pharmaceutical and generic medicines. The company has two operating divisions globally: Innovative medicines and Sandoz for biosimilars and generic pharmaceuticals.

Product Portfolio:

Durezol: It is a topical corticosteroid which is indicated for pain and inflammation treatment linked with ocular surgery and endogenous anterior uveitis treatment.

Key Development: In June 17, 2022, Sandoz, a generic and biosimilar medicines provider, announced about application acceptance for high concentration formulation of its biosimilar Hyrimoz (adalimumab) by the European Medicines Agency (EMA) for regulatory review. The application covers all indications, including rheumatoid arthritis, uveitis, Crohn's disease, ulcerative colitis and plaque psoriasis

The global uveitis market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing product pipeline of pharma companies
      • 4.1.1.2. Rising advancements in technologies leading to the development of new drugs
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost associated with treatment
      • 4.1.2.2. High risk of side effects
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Uveitis Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
    • 7.1.2. Market Attractiveness Index, By Uveitis Type
  • 7.2. Anterior Uveitis *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Intermediate Uveitis
  • 7.4. Posterior Uveitis
  • 7.5. Pan Uveitis

8. By Medications

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
    • 8.1.2. Market Attractiveness Index, By Medications
  • 8.2. Corticosteroids *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 8.2.3. Bethamethasone
    • 8.2.4. Dexamethasone
    • 8.2.5. Cortisone
    • 8.2.6. Triamcinolone
    • 8.2.7. Methylprednisolone
  • 8.3. Anti-Rheumatic Drugs
    • 8.3.1. Mycophenolate
    • 8.3.2. Cyclosporine
    • 8.3.3. Azathioprine
    • 8.3.4. Tacrolimus
  • 8.4. Cycloplegic-Mydriatic Drugs
    • 8.4.1. Tropicamide
    • 8.4.2. Cyclopentolate
    • 8.4.3. Phenylephrine
    • 8.4.4. Homatropine
    • 8.4.5. Atropine
  • 8.5. Immunomodulatory Therapy
    • 8.5.1. Azathioprine
    • 8.5.2. Methotrexate
    • 8.5.3. Mycophenolate Mofetil
    • 8.5.4. Cyclosporine
  • 8.6. Biological Therapy
    • 8.6.1. Infliximab
    • 8.6.2. Adalimumab
    • 8.6.3. Daclizumab
    • 8.6.4. Interferon-Alfa
  • 8.7. Anti-Viral Drugs
    • 8.7.1. Aciclovir
    • 8.7.2. Valaciclovir
  • 8.8. Others

9. By Medication Form

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
    • 9.1.2. Market Attractiveness Index, By Medication Form
  • 9.2. Eye Drops *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Pills
  • 9.4. Injections
  • 9.5. Implants

10. By End-User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.1.2. Market Attractiveness Index, By End-User
  • 10.2. Hospital Pharmacies *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Uveitis Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication Form
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Products Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Novartis AG *
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. AbbVie
  • 13.3. Johnson & Johnson Services, Inc.
  • 13.4. Amgen
  • 13.5. Alimera Sciences
  • 13.6. Bausch & Lomb Incorporated.
  • 13.7. Kiora Pharmaceuticals, Inc.
  • 13.8. Santen Pharmaceutical Co., Ltd.
  • 13.9. EyePoint Pharmaceuticals, Inc.
  • 13.10. Clearside Biomedical

LIST NOT EXHAUSTIVE

14. Global Uveitis Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Medications
  • 14.3. Contact Us